Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

by Bachier, C., Bai, J., Batrakou, D., Blumenschein, G.R, Broad, R., Devarakonda, S., Doger de Spéville, B., Edelman, M.J, Fayngerts, S., Fracasso, P.M, Frigault, M.J, Gainor, J., Gerry, A., Govindan, R., Heymach, J.V, Holdich, T., Hyland, N., Johnson, M., Lam, V.K, Marks, D., Moreno, V., Navenot, J.-M, Norry, E., Olszanski, A.J, Pentony, M.M, Sanderson, J.P, Wolchinsky, Z.
Published 2022

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

by Abdel-Wahab, N., Altan, M., Blumenschein, G.R, Buni, M., Campbell, M.T, Cascone, T., Chu, Y., Davies, M.A, Diab, A., Futreal, A., Garcia-Manero, G., Gibbons, D.L, Hussain, Z., Hwu, P., Kim, S.T, Kramer, J., Lim, B., Loghin, M.E, Lu, C., Lu, H., Misoi, M., Naing, A., Neelapu, S.S, Nurieva, R., Oliva, I.C.G, Patel, S.P, Rodriguez, E., Shah, A.Y, Suarez-Almazor, M.E, Tannir, N.M, Tawbi, H.A, Tayar, J.H, Tu, J., Valero, V., Wang, J., Wang, L., Westin, S.N, Zou, J.
Published 2022

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

by Abdel-Wahab, N., Altan, M., Blumenschein, G.R, Buni, M., Campbell, M.T, Cascone, T., Chu, Y., Davies, M.A, Diab, A., Futreal, A., Garcia-Manero, G., Gibbons, D.L, Hussain, Z., Hwu, P., Kim, S.T, Kramer, J., Lim, B., Loghin, M.E, Lu, C., Lu, H., Misoi, M., Naing, A., Neelapu, S.S, Nurieva, R., Oliva, I.C.G, Patel, S.P, Rodriguez, E., Shah, A.Y, Suarez-Almazor, M.E, Tannir, N.M, Tawbi, H.A, Tayar, J.H, Tu, J., Valero, V., Wang, J., Wang, L., Westin, S.N, Zou, J.
Published 2022